Dipraglurant

DRUG3 trials

Sponsors

Addex Pharma S.A.

Conditions

BlepharospasmDyskinesia, Drug-InducedDyskinesiasDystoniaParkinson Disease

Phase 2

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

TerminatedNCT04857359

Addex Pharma S.A.Dyskinesia, Drug-Induced, Dyskinesias, Parkinson Disease

Start: 2021-08-06End: 2022-08-15Updated: 2025-08-06

Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm

CompletedNCT05027997

Addex Pharma S.A.Blepharospasm, Dystonia

Start: 2021-10-06End: 2022-11-27Updated: 2025-10-03

Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

TerminatedNCT05116813

Addex Pharma S.A.Dyskinesia, Drug-Induced, Dyskinesias, Parkinson Disease

Start: 2021-10-25End: 2022-08-15Updated: 2025-08-06